Concepedia

Amal Melhem‐Bertrandt

AM

26

Publications

2.5K

Citations

20

H-Index

2010

Active since

Affiliations

Astellas Pharma (United States)(Current)

Seagen (United States)

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

The Barbara Ann Karmanos Cancer Institute

Amal Melhem‐Bertrandt is an author at Astellas Pharma (United States) specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2010–2021

26

Publications

26

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 598 citations · Full text

Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer

Amal Melhem‐Bertrandt, Mariana Chávez‐MacGregor, Xiudong Lei et al. · Journal of Clinical Oncology · 2011 · 449 citations · Full text

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang et al. · Journal of Clinical Oncology · 2020 · 311 citations · Full text

Early onset HER2‐positive breast cancer is associated with germline <i>TP53</i> mutations

Amal Melhem‐Bertrandt, Jasmina Bojadzieva, Kaylene Ready et al. · Cancer · 2011 · 133 citations · Full text

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

Johann S. de Bono, Simon Chowdhury, Susan Feyerabend et al. · European Urology · 2017 · 114 citations · Full text

Rows per page

1–5 of 26